SLC5A7 and acute myeloid leukemia: In the final PSM cohort, 197 patients were assigned to each de novo AML and t-AML with CHT or RT alone group (Supplemental Table 5), and 72 patients were assigned to each de novo AML and t-AML with the CHT + RT group (Supplemental Table 6), respectively.